Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus

Source:
GOV UK
Publisher:
Medicines and Healthcare products Regulatory Agency
Publication date:
21 November 2019

Abstract

Establish hepatitis B status before initiating carfilzomib and in patients with unknown hepatitis B virus serology who are already being treated with carfilzomib.